Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Late-stage cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In situ detection of early stages and late stages HPV einfection
ActiveUS20090311668A1Microbiological testing/measurementImmunoglobulinsCancers diagnosisMonoclonal antibody
Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and / or late stage HPV-associated or HPV-specific cancers. The anti-HPV antibodies are used in performing immunological assays on clinical samples. Various immunological assays and kits for detecting HPV infection, cervical cancer, other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression are also provided.
Owner:HEER MEDICAL TECH DEV CO LTD
Conotoxin MVII A and Trx fusion protein and its expression and application
InactiveCN1487085AHigh analgesic activityEasy extractionNervous disorderPeptide/protein ingredientsEscherichia coliConotoxin
The present invention provides one kind of conotoxin MVII A and Trx fusion protein and its expression and application. Trx-CTX MVII A fusion protein is first cloned and expressed in colibacillus and then chromatographicaly purified, reduced and oxidized to obtain active Trx-CTX MVII A fusion protein. The obtained fusion protein may be applied in preparing analgetic for late stage cancer and AIDS and that for post-operation pain, burns, etc. and may be also applied in preparing medicine for cerebral ischemia and cerebral demage owing to its nerve protecting function. The present invention can obtain fusion protein with great molecular weight and relatively long half time, and may be applied in medicine development directly or as intermediate to be enzyme incised to obtain active omiga-conotoxin MVII A for further medicine development.
Owner:ZHEJIANG UNIV
Novel monoclonal antibodies against HPV proteins
ActiveUS20090312527A1Microbiological testing/measurementImmunoglobulins against virusesCancers diagnosisDisease cause
Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and / or late stage HPV-associated or HPV-specific cancers. Various monoclonal antibodies recognizing specific epitope for specific HPV protein or HPV type, common epitope for various HPV proteins or HPV types are obtained. These obtained monoclonal antibodies are useful tools in early clinical detection of HPV infection and general detection of HPV related diseases, specific detection of invasive cervical cancer, detection of other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression.
Owner:HEER MEDICAL TECH DEV CO LTD
Detection, screening, and diagnosis of HPV-associated cancers
ActiveUS8968995B2Microbiological testing/measurementBiological material analysisScreening methodSpecific protein
Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and / or late HPV-associated or HPV-specific proteins or antibodies. Mononoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of various HPV associated cancers are provided. HPV associated cancer biomarkers are identified and can be used in a screening method for early stage precancerous lesions as well as late stage cancer progression.
Owner:HEER MEDICAL TECH DEV CO LTD
Anti-angiogenic cellular agent for cancer therapy
InactiveUS20080260701A1Effective treatmentTherapeutically effectiveBiocideGenetic material ingredientsAbnormal tissue growthHematopoietic cell
The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.
Owner:HOPE ERNEST G
Targeting-enhanced anticancer nanoparticles and preparation methods of same
ActiveUS20150290332A1Maximized tumor targetingMaximized drug deliveryPowder deliveryLuminescence/biological staining preparationSide effectTumor targeting
This invention encompasses targeting-enhanced anticancer nanoparticles and preparation methods for the same. In particular, this invention provides targeting-enhanced anticancer nanoparticles comprising non-covalently bound anticancer drugs, serum albumins as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties. The targeting-enhanced anticancer nanoparticles described in the present invention are characterized by non-covalently bound constituents: anticancer drugs, serum albumin as the nanoparticle base material, and porphyrin compounds as tumor-targeting moieties, thus preventing common toxic side effects, enhancing the structural stability of nanoparticles, and enhancing tumor targeting by treatment with electromagnetic waves due to the activity of porphyrin, without structural and functional changes. Taken together, the present invention provides a chemotherapeutic method that maximizes drug delivery / tumor targeting and is expected to be a successful therapy for both early-stage and late-stage cancer.
Owner:JINIS
IN SITU detection of early stages and late stages HPV infection
InactiveUS20100003704A1Microbiological testing/measurementImmunoglobulinsEarly carcinomaAntiendomysial antibodies
Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and / or late HPV-associated or HPV-specific proteins or antibodies. Mononoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of invasive cervical cancer are provided. Cervical cancer biomarkers are identified and can be used in a detection method for early stage precancerous lesions as well as late stage cancer progression.
Owner:ONCOHEALTH
Methods of metabolic targeting cancer cells using che mo- and immunotherapy for treating cancer
ActiveCN103347521AHeavy metal active ingredientsPeptide/protein ingredientsTherapeutic antibodyRegimen
Methods for treating cancer comprising administering a metabolic targeting chemo-immunotherapy regimen are provided herein. In one embodiment, the metabolic targeting chemo-immunotherapy regimen may include steps of administering a therapeutically effective dose of one or more immunologic agents (e.g., a therapeutic antibody) to stimulate an immune response in a subject having cancer; reducing the patient's blood glucose level; and administering a therapeutically effective dose of one or more chemotherapeutic agents. The methods desecribed herein may be used to treat any type of cancer, especially malignant and metastatic late stage cancers.
Owner:汤姆 C 臧
G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
ActiveUS20130183317A1Inhibit progressSugar derivativesMicrobiological testing/measurementTumor BiomarkersG protein-coupled receptor
A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng / ml was developed.
Owner:TEMPLE UNIVERSITY
G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
ActiveUS20120219570A1SamplingMicrobiological testing/measurementTumor BiomarkersG protein-coupled receptor
A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng / ml was developed.
Owner:TEMPLE UNIVERSITY
Detection, screening, and diagnosis of HPV-associated cancers
ActiveUS20100120019A1Access riskMicrobiological testing/measurementBiological material analysisSpecific detectionTumor Biomarkers
Embodiments of the invention provide methods, polyclonal antibodies, monoclonal antibodies, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and / or late HPV-associated or HPV-specific proteins or antibodies. Monoclonal antibodies are used to detect oncogenic high risk and low risk HPV types in a single assay, which is not limited to assay type or format. Useful tools for specific detection of various HPV associated cancers are provided. HPV associated cancer biomarkers are identified and can be used in a screening method for early stage precancerous lesions as well as late stage cancer progression.
Owner:HEER MEDICAL TECH DEV CO LTD
Fungal medicinal granules for inducing suicide of cancer cell
InactiveCN101411720APrevent proliferationInhibited DiffusionOrganic active ingredientsEnergy modified materialsSide effectCancer cell
The invention provides fungus medicinal granules for inducing cancer cells to suicide. The prior anticancer medicine and the prior treatment method have large side effect and high recurrence rate, thereby bringing great pain and economic burden for patients and families. Aiming to solve the problems, the invention provides instant medicinal granules prepared from active factors of a fungus extract for stimulating and advancing immune function, promoting self-destruction of the cancer cells and inducing the suicide of the cancer cells. The prepared instant medicinal granules have high recurrence rate, no recrudescence, no toxicity or side effect, and are suitable for various middle-stage and late-stage cancer patients.
Owner:林树芳
chromatin peptide for blocking human HIF-1 alpha gene and regulating network downstream related gene
ActiveCN100418574CPeptide/protein ingredientsInanimate material medical ingredientsFhit geneBlood vessel
Disclosed is a category of chromatin peptide medicinal molecules capable of blocking human cell anoxybiotic reaction channels, the molecules are DNA compatible structure domain sequences of the related transcription factors or their bionic molecules or derivatives containing 5-100 amino acid residues, they can be specifically bond to HIF-1 alpha self-promotors or transcription factor driven over 40 downstream gene promotors expressed thereby, the molecules can close the molecular channels for cell anoxybiotic reactions including cell sugar glycolysis reaction and / or immunological inflammation reaction and / or vessel generation reaction, thus closing the non-controlled propagation of late stage cancer cells or chronic inflammation cells under anoxybiotic conditions.
Owner:王成球 +3
Targeting-enhanced anticancer nanoparticles and preparation methods of same
ActiveUS20170239369A1Reduce efficacyMaintain propertiesPowder deliveryLuminescence/biological staining preparationSerum protein albuminSide effect
Owner:JINIS
G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng / ml was developed.
Owner:TEMPLE UNIVERSITY
Tumor curing medicine containing saussurea involucrate and preparation method thereof
InactiveCN101862395ASymptoms improvedAnthropod material medical ingredientsHydroxy compound active ingredientsMyrrhAdemetionine
The invention discloses a tumor curing medicine containing saussurea involucrate, which is a preparation prepared from the following raw materials in parts by weight: 5 to 25 parts of saussurea involucrate, 20 to 40 parts of safflower, 5 to 25 parts of scorpion, 4 to 16 parts of liquorice, 20 to 40 parts of datura stramonium seeds, 5 to 25 parts of myrrh, 20 to 40 parts of frankincense, 20 to 40 parts of borneol, 5 to 25 parts of silkworm larva, 4 to 16 parts of rheum officinale, 4 to 16 parts of fructus papaveris, 4 to 16 parts of castor, 4 to 16 parts of red-rooted salvia, 4 to 16 parts of ligusticum wallichii and 5 to 25 parts of patrinia heterophylla. The whole formula is crushed to 80 to 120 mesh and is further prepared into required patches, Papua agent, oral liquid, granules or capsules. The medicine significantly improves the softening, the reducing and the control of clinical lung, stomach, liver, colorectal, breast, esophagus, bladder and other middle- and late-stage cancer as well as severe pain, upset insomnia and other symptoms caused by tumors.
Owner:饶峰
Anti-angiogenic cellular agent for cancer therapy
InactiveUS20080248002A1Least riskEffective treatmentBiocideGenetic material ingredientsAbnormal tissue growthHematopoietic cell
The invention provides cytokine induced killer (CIK) cell populations and methods of using CIK cells to treat cellular proliferative disorders. CIK cells generated in vitro include both bulk cultures and clones. Individual CIK cell clones display distinct but overlapping lytic specificities for tumor cells and endothelial cells in vitro. When injected in vivo, bulk CIK cell cultures selectively attack tumor tissue. CIK cells can be used to treat a variety of cellular proliferative disorders, including early and late stage cancers as well as hematopoietic cell and solid tissue tumors.
Owner:HOPE ERNEST G
Conotoxin MVII A and Trx fusion protein and its expression and application
InactiveCN1228446CSimple processQuality improvementNervous disorderPeptide/protein ingredientsEscherichia coliConotoxin
The present invention provides one kind of conotoxin MVII A and Trx fusion protein and its expression and application. Trx-CTX MVII A fusion protein is first cloned and expressed in colibacillus and then chromatographicaly purified, reduced and oxidized to obtain active Trx-CTX MVII A fusion protein. The obtained fusion protein may be applied in preparing analgetic for late stage cancer and AIDS and that for post-operation pain, burns, etc. and may be also applied in preparing medicine for cerebral ischemia and cerebral demage owing to its nerve protecting function. The present invention can obtain fusion protein with great molecular weight and relatively long half time, and may be applied in medicine development directly or as intermediate to be enzyme incised to obtain active omiga-conotoxin MVII A for further medicine development.
Owner:ZHEJIANG UNIV
Classifier for predicting ICI drug application sensitivity of advanced tumor patients and application
PendingCN113981077APredictive sensitivityProlong lifeHealth-index calculationMicrobiological testing/measurementStage tumorDrugs sensitivity
The invention discloses a classifier for predicting ICI drug application sensitivity of advanced tumor patients and application of the classifier. The target of predicting the sensitivity of the advanced tumor patients to the ICI drugs is achieved by detecting the tumor mutation burden (TMB) through sequencing and classifying the patients according to the classifier, the accuracy of defining the crowd of the advanced tumor patients applying the ICI drugs is improved, and the method has great significance in relieving the economic burden of the patients and prolonging the lifetime of the patients.
Owner:罗俊航 +4
Medicine for reinforcing primordial qi of late stage cancer patents
InactiveCN1628823AActivate or enhance lethalityProlong lifeUnknown materialsAntineoplastic agentsLigustrum japonicumRhizome
The invention provides a medicine for reinforcing primordial qi of late stage cancer patients, which is prepared from broomrape, prepared rehmannia root, pilose asiabell root, ligustrum japonicum, Chinese angelica root, white atractylodes rhizome, astragalus root, schisandra fruit, root of herbaceous peony, Poria cocos, and can be made into the dosages forms of oral liquid, powder, tablet, capsule, and granulated electuary.
Owner:曾隆江
G-protein coupled receptor-associated sorting protein 1 as a cancer biomarker
Owner:TEMPLE UNIVERSITY
Traditional Chinese medicine for treating tumors and cancers and using method thereof
InactiveCN106728334AGood effectImprove securityDispersion deliveryAntineoplastic agentsDiseaseSide effect
The invention discloses a traditional Chinese medicine for treating tumors and cancers and a using method thereof. The traditional Chinese medicine comprises six formulae and is taken by means of special methods according to illness degrees. If the traditional Chinese medicine is used for mild tumors, the tumors can fully disappear; and the effective rate of the traditional Chinese medicine for treating early-stage, middle-stage and late-stage cancers is higher than 90%. The traditional Chinese medicine for treating tumors and cancers, provided by the invention, can improve blood and block agglomerated components of the tumors and cancer blocks in positions of a body, so that the tumors and cancer blocks are softened and shrunk and are eliminated. The anti-tumor and anti-cancer ability in the body is enhanced, and the body gets rid of entanglement of diseases, so that the body is emancipated. The traditional Chinese medicine has the advantages of being quick to take effect, obvious in effect, high in safety, free of side effects and the like, and has curative effects on various types of malignant tumors and benign tumors in systems and positions of the human body.
Owner:陈光荣
Oncotherapy type heparanase MAP vaccine
InactiveCN102133397AOvercoming resistance to small molecular weightOvercome the shortcomings of weak originalityPeptide/protein ingredientsAntibody medical ingredientsAntitumor immunityTumor therapy
The invention relates to epi-position MAP vaccine which can induce effective antitumor immunity effect in the tumor associated antigen heparanase protein sequence. The vaccine overcomes the defects of single-peptide vaccine that the molecular weight is small and the antigenicity is weak, can induce strong heparanase specific cell toxicity T lymphocyte, and generates killing effect on positive tumor cells of heparanase of different tissues and organs, so that the multi-peptide vaccine can be prepared and used for curing middle or late-period tumors.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Particle size purification method and devices
ActiveUS11162880B2Quick analysisSmall amount requiredMembranesPreparing sample for investigationMalariaNeurological disorder
A particle separation multi-membrane matrix device and method are provided. The particles isolated may comprise nano-scale particles, such extracellular membrane vesicles, having a size of about 50 to about 150 nm. The vesicles are released by many different cell types, and may be efficiently isolated at high yield and purity according to the present methods from various body fluids (e.g., blood, saliva, breast milk, serum, plasma, ascites fluid, etc.). Such isolated exosome preparations may include biomarkers, such as disease biomarkers (diagnostic markers) for various disease (early stage and late stage cancers, neurological disorders (Parkinson disease, Alzheimer disease), diabetes, pancreatic diseases, renal failure, infectious diseases (HIV, tuberculosis, malaria, hepatitis)). The present methods and devices may be used to detect and monitor animals (human, livestock, companion animal) for infectious diseases, such as tuberculosis and other diseases. The methods and devices require minimal sample material (10 μl), are rapid, economical, yield highly enriched small molecule (eg, exosomes) preparations, and do not require electricity.
Owner:UNIV OF NOTRE DAME DU LAC
Chinese medicinal composition with anticancer effect, and preparation method and application
PendingCN108514613AReduce vitalityImprove the immunityOrganic active ingredientsFungi medical ingredientsSalvia miltiorrhizaBletilla striata
The invention discloses a traditional Chinese medicine composition with anticancer effect and preparation method and application thereof. The traditional Chinese medicine composition with anticancereffect comprises the following raw materials: salvia miltiorrhiza, chinese yam, atractylodes macrocephala, bletilla striata, solanum nigrum, marjorie, sichuan lovage rhizome, achyranthes bidentata, rhizoma paridis, rhizoma phragmitis and houttuynia cordata. The traditional Chinese medicine composition with anticancer effect follows the compatibility principle of Chinese Medicine, can reduce the vitality of cancer cells, improve the immunity of the human body, enhance the resistance to cancer cells, treat both the symptoms and root causes, have good curative effect on early, middle and late stage cancer symptoms such as prostate cancer, liver cancer, gastric cancer, lung cancer, esophagus cancer and the like.
Owner:金志华
Traditional Chinese medicament for treating tumors
InactiveCN101979019AInhibition of killingAnti-cancerAntineoplastic agentsPlant ingredientsCancer cellTraditional medicine
The invention relates to a traditional Chinese medicine for treating tumors and provides a traditional Chinese medicine prepared mainly from Camellia nitidissima and phoenix-tail fern for treating tumors. The invention adopts a technical scheme that: the main ingredients comprise 10 to 90 percent of Camellia nitidissima and 10 to 90 percent of phoenix-tail fern; and one preparation method of the traditional Chinese medicine is to decoct the Camellia nitidissima and phoenix-tail fern to obtain paste, add auxiliary materials and form the mixture into honeyed pills or other formulations of traditional Chinese medicine and the other preparation method is to crush the Camellia nitidissima and phoenix-tail fern into powder or micro powder, mix gynostemma pentaphylla powder (micro powder) with the phoenix-tail fern powder (micro powder) uniformly, add auxiliary materials and form the mixture into capsules or electuary. The traditional Chinese medicine has the effects of heat clearing, detoxifying, xeransis, blood cooling, blood bleeding stopping and bacterium and inflammatory resisting, has anticancer, cancer-preventing, cancer cell inhibiting and killing functions and other functions and is suitable for treating patients with tumor in early, middle and late stages.
Owner:蒋科富
Targeting-enhanced anticancer nanoparticles and preparation methods of same
ActiveUS9662401B2Reduce efficacyMaintain propertiesPowder deliveryLuminescence/biological staining preparationSide effectSerum protein albumin
Owner:JINIS
Chinese medicinal enteric-coated capsule for middle and advanced stage tumors and chronic hepatitis B and preparation method thereof
ActiveCN105055455AAvoid hypoxiaAvoid fatigueAmphibian material medical ingredientsAntiviralsCelluloseSide effect
The invention discloses a Chinese medicinal enteric-coated capsule for middle and advanced stage tumors and chronic hepatitis B and a preparation method thereof. The Chinese medicinal enteric-coated capsule is prepared by processing of drug active component processed from dried toad skin and a pharmaceutical acceptable carrier according to certain proportion. The pharmaceutical acceptable carrier consists of carboxymethylcellulose sodium and starch. Compared with the prior art, the Chinese medicinal enteric-coated capsule provided by the invention adopts 70% ethanol for percolation extraction, the content of the effective components of indole alkaloids and bufogenin is enhanced, the curative effect is strengthened, the toxic and side effects of the drug are reduced, the drug can achieve significant curative effect after taking by patients, and is safer and more convenient.
Owner:陕西东泰制药有限公司
Biological compound for treating cancer, and preparation method and application of biological compound
InactiveCN109847074AAvoid damageThe synthesis steps are simpleRadioactive preparation carriersPharmaceutical non-active ingredientsCancer cellMedicine
The invention discloses a biological compound for treating cancer, and a preparation method and application of the biological compound. The biological compound is a radioactive isotope labelled DNA fragment. The preparation method of the biological compound for treating cancer comprises two steps of performing PCR amplification and labelling radioactive isotope and performing G50 gel column chromatography. The preparation method is simple. According to the biological compound for treating cancer, the radioactive isotope can be directly guided into cancer cells in a targeted manner without packaging, and the purpose of treating the cancer without damaging the normal tissue of a human body can be achieved, and the biological compound is suitable for treating primary lesion of the cancer, ortransferred cancer, primary liver cancer and late stage cancer.
Owner:孔彦平
Medicine for reinforcing primordial qi of late stage cancer patents
InactiveCN1330338CActivate or enhance lethalityProlong lifeAntineoplastic agentsPlant ingredientsLigustrum japonicumRhizome
Owner:曾隆江
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com